title: Decreased delta-sleep and plasma delta-sleep-inducing peptide in patients with Cushing syndrome.
abstract: To evaluate the sleep disturbances of patients with Cushing syndrome and to examine the relationship between the sleep disturbances and plasma levels of delta-sleep-inducing peptide-like immunoreactivity (DSIP-LI), we performed three polysomnographic/endocrinological studies in patients with Cushing syndrome. In study 1, polysomnography was studied in 12 patients and 12 matched normal volunteers. In addition, DSIP-LI was measured every 30 min for 24 h in 9 patients with Cushing syndrome and 12 normal volunteers. The percentage of time spent in delta sleep (stages 3 and 4) was significantly reduced in patients with Cushing syndrome (5.8 +/- 1.4%; mean +/- SEM) compared to normal volunteers (14.0 +/- 2.5%) (p < 0.01). REM sleep indices, however, were not significantly different between the two groups. There was a significant negative correlation between amount of delta sleep and 08.00 h DSIP-LI (r = -0.43, p < 0.05), which is against the notion of a causal relationship between DSIP-LI and delta sleep. The circadian rhythm of plasma DSIP-LI was found to be similar in Cushing patients and normal volunteers. In study 2, we measured plasma levels of delta-sleep-inducing peptide-like immunoreactivity (DSIP-LI) at 08.00 h in 65 patients with Cushing syndrome and 49 normal volunteers. The 08.00 h DSIP-LI concentrations of 797 +/- 57 pmol/l (mean +/- SEM) in the patients with Cushing syndrome were significantly reduced compared to the level of 1,062 +/- 99 pmol/l found in the normal volunteers (p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Laboratory of Developmental Neurobiology, NICHD, National Institutes of Health, Bethesda, MD 20892.
authors.forename: T C
authors.initials: TC
authors.lastname: Friedman
authors.forename: D
authors.initials: D
authors.lastname: García-Borreguero
authors.forename: D
authors.initials: D
authors.lastname: Hardwick
authors.forename: C N
authors.initials: CN
authors.lastname: Akuete
authors.forename: J L
authors.initials: JL
authors.lastname: Doppman
authors.forename: L D
authors.initials: LD
authors.lastname: Dorn
authors.forename: C N
authors.initials: CN
authors.lastname: Barker
authors.forename: J A
authors.initials: JA
authors.lastname: Yanovski
authors.forename: G P
authors.initials: GP
authors.lastname: Chrousos
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D016022:Case-Control Studies; D003346:Corticotropin-Releasing Hormone / Q000008:administration & dosage / Q000494:pharmacology; D003480:Cushing Syndrome / Q000097:blood / Q000503:physiopathology*; D003701:Delta Sleep-Inducing Peptide / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017591:Petrosal Sinus Sampling; D010902:Pituitary Gland / Q000378:metabolism; D012894:Sleep Stages / Q000502:physiology*; D012893:Sleep Wake Disorders / Q000209:etiology; D012895:Sleep, REM / Q000502:physiology
chemical_list: D003701:Delta Sleep-Inducing Peptide; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone